KD01 for bladder cancer: a safety and early efficacy trial
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called KD01, which is given directly into the bladder through a catheter (intravesical instillation) for bladder cancer. It aims to see if the drug is safe and tolerable, and if it may help slow or stop the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific type of bladder cancer: either non-muscle-invasive (high-risk) or muscle-invasive (stage cT2-4aN0-1M0).
- If you have non-muscle-invasive cancer, you must have tried BCG treatment and it either didn't work or your cancer came back within a certain time.
- You must be between 18 and 75 years old and in reasonably good general health (ECOG performance status 0 or 1).
- Your blood counts, liver, kidney, and heart function must be within normal limits.
- You cannot have had prior treatment with adenovirus-based therapies, pelvic radiation in the last 5 years, or certain other cancer treatments recently.
- You must be willing to use effective contraception during the study and for 6 months after the last dose (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
This trial tests a new drug called KD01 for women with advanced gynecologic cancers (like cervical or endometrial cancer) that haven't responded to other treatments. It also has a separate part for younger women who want to preserve their fertility.
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
Hear when a new Bladder Cancer (BC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.